Key result
DOACs offer advantages over warfarin for AFib stroke prevention but require specific primary care considerations.
Why the study?
DOACs offer advantages over warfarin for stroke prevention in AF, warranting an overview of evidence and guidance on selection and initiation in primary care.
Do direct oral anticoagulants (DOACs) prevent stroke in patients with atrial fibrillation compared to warfarin?
Do direct oral anticoagulants (DOACs) prevent stroke in patients with atrial fibrillation compared to warfarin?
This review outlines the advantages of DOACs over warfarin for stroke prevention in AF and provides guidance for primary care clinicians on drug selection and initiation.
Supports DOAC preference in AF stroke prevention; leaves open optimal primary care initiation protocols.
Anticoagulation with direct oral anticoagulants (DOAC) is becoming increasingly more prominent for stroke prevention in patients with Atrial Fibrillation (AF). Whereas a vitamin k analogue like warfarin would traditionally be used for this; DOACs offer several advantages over warfarin. This review article will provide an overview of the current evidence supporting the use of DOACs for anticoagulation in AF and how a primary care clinician would go about choosing which DOACs to choose and considerations that need to be taken before initiation of the drug.
No takes yet. Share an insight, caveat, or question.
Rahman et al. (2024) conducted a review in Atrial Fibrillation. Direct Oral Anticoagulants (DOACs) vs. Warfarin was evaluated on Stroke prevention. Direct oral anticoagulants offer several advantages over warfarin for stroke prevention in patients with atrial fibrillation, with specific considerations required for initiation in primary care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: